• FR
  • Inform me about new class actions

    • This field is for validation purposes and should be left unchanged.

    Coming soon

    Notice about our registration form
    Completing the form does not guarantee you any compensation

    Please note that completing this form does not guarantee you any compensation.

    Indeed, it will ultimately be up to the court to decide on the merits of the class action and the terms of compensation. In addition, the eligibility criteria to receive compensation could be modified by the court, which could result in your exclusion from the class action.

    Please also note that we will not conduct a detailed analysis of each individual case until there is a final judgment or settlement in the file. Completing this form does not mean that you are eligible.

    We will inform the people who have registered of any final outcome in the class action. We will communicate with them by email. We invite you to notify us of any changes to your email address.

    We also invite you to keep informed through our website which we will update regularly.

    We thank you for your interest in this class action.

    Continue

    Ongoing class actions

    Camilo Baratto v. Merck Canada Inc. and Merck Frosst Canada & co

    Propecia and Proscar

    The class action seeks to compensate every person who suffered an injury following the use of Propecia or Proscar (scientifically known as finasteride) for the treatment of male pattern hair loss.

    The motion alleges the liability of Merck Canada and Merck Frosst Canada due to the fact that they promoted their medication as a treatment for male pattern hair loss while they were aware, or should have been aware, that their product warnings regarding side effects were inadequate.

    Latest news

    On January 23, 2018, we argued the appeal of the judgment dismissing the authorization of the class action before the Court of Appeal, which took the case under advisement.

    On July 26, 2018, in a unanimous judgment, the Quebec Court of Appeal authorized the class action.

    Are you a member?

    The class is defined as follows in the motion seeking authorization:

    All persons residing in Quebec who have been prescribed Propecia and/or Proscar for the treatment of male pattern baldness before November 18, 2011 and who have developed at least one of the following conditions, which has persisted following the discontinuation of use :

    • Sexual dysfunction;
    • Decreased libido;
    • Erectile dysfunction;
    • Ejaculatory disorders;
    • Decreased volume of ejaculate;
    • Shrinking of the genitals;
    • Gynecomastia;
    • Testicular pain;
    • Anhedonia and difficulty reaching an orgasm, or;
    • Depression.

    If you think you are a class member and would like to receive information on the file, you can sign up to our mailing list by filling the registration form below.

    For more information on class actions, see our section entitled « What are class actions ? »

    The Class Action

    In April 2013, Mr. Baratto filed a motion seeking authorization to institute a class action (the “motion seeking authorization”) against Merck Canada Inc. and Merck Frosst Canada & co.

    On December 21st, 2016, the Honourable Claude Dallaire dismissed the application for leave to institute a class action against Merck Canada and Merck Frosst Canada, which was argued on January 27 and 28, 2016.

    Your representative Camilo Baratto and we, your prosecutors, have decided to appeal this judgment, which, in our view, contains several errors of fact and of law. The hearing at the Quebec Court of Appeal was held on January 23, 2018.

    On July 26, 2018, in a unanimous judgment, the Quebec Court of Appeal authorized the class action.

     

    Registration for class actions

    > Notices about our registration form
    • This field is for validation purposes and should be left unchanged.